Cramer, P., von Tresckow, J., Robrecht, S., Bahlo, J., Furstenau, M., Langerbeins, P., . . . Hallek, M. (2020). Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: Primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO). Haematologica.
Chicago-stil citatCramer, Paula, et al. "Bendamustine Followed By Ofatumumab and Ibrutinib in Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of a Multicenter, Open-label, Phase II Trial (CLL2-BIO)." Haematologica 2020.
MLA-referensCramer, Paula, et al. "Bendamustine Followed By Ofatumumab and Ibrutinib in Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of a Multicenter, Open-label, Phase II Trial (CLL2-BIO)." Haematologica 2020.